- Big catkin willow acids compounds and medical use
-
The invention discloses a AMPK agonist activity with salicylic acid compound and its preparation method and medical use, it is the structural formula of the formula (I) compound of formula, its pharmaceutically acceptable salt or prodrug or solvate. The structure of the invention of formula (I) compound of formula activated AMPK, therefore can be used for preparing the prevention or treatment of AMPK mediated diseases.
- -
-
-
- Bavachinin analogues as agonists of pan-peroxisome proliferator-activated receptors
-
Peroxisome proliferator-activated receptors (PPARs) agonists contribute to the regulation of glucose, lipid, and cholesterol metabolism and have emerged as key targets to treat metabolic syndrome. In our previous study, the natural compound bavachinin was found to have pan-PPAR agonist activity. In this study, five isoflavones, three isoflavanones, and five scaffold-hopping analogues of bavachinin were designed, synthesised, and evaluated through reporter gene assays for pan-PPAR agonist activity. The analogue 2-(4-hydroxyphenyl)-6-isopentenyl-7-methoxy-2,3-dihydroquinolin-4(1H)-one (21) was identified as a pan-PPAR agonist, exhibiting substantially higher PPAR α/β agonist activity and equal PPAR-γ agonist activity than does bavachinin.
- Yi, Jingyu,Du, Guoxin,Zhao, Yuanyuan,Zhang, Liuqiang,Li, Bo,Zhu, Weiliang,Huang, Cheng,Li, Yiming,Guo, Fujiang
-
p. 1851 - 1862
(2018/06/18)
-
- ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE
-
The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. (I) wherein each symbol is as described in the specification, or a salt thereof.
- -
-
Paragraph 0342
(2015/11/10)
-
- N-1H-tetrazol-5-ylbenzamides having use as antiallergy and antiinflammatory agents
-
The present invention is novel 2-isopropoxy-N-1H-tetrazol-5-yl-benzamides having unexpected inhibition of histamine release from human basophils.
- -
-
-